SIGNATURES for Haemonetics (HAE)

Send us Feedback

Haemonetics (HAE)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

HAE » Topics » SIGNATURES

These excerpts taken from the HAE 10-K filed May 22, 2009.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HAEMONETICS CORPORATION


	By:	/s/ Brian Concannon

Brian Concannon,
President and Chief Executive Officer

Date: May 22, 2009

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.


Signature	Title	Date


/s/ Brian Concannon Brian Concannon	President and Chief Executive Officer, (Principal Executive Officer)	May 22, 2009

/s/ Christopher Lindop Christopher Lindop	Chief Financial Officer and Vice President Business Development, (Principal Financial Officer)	May 22, 2009

/s/ Susan Hanlon Susan Hanlon	Vice President Finance, (Principal Accounting Officer)	May 22, 2009

/s/ Brad Nutter Brad Nutter	Executive Chairman of the Board	May 22,2009

/s/ Lawrence Best Lawrence Best	Director	May 22, 2009

/s/ Susan Bartlett Foote Susan Bartlett Foote	Director	May 22, 2009

/s/ Ronald Gelbman Ronald Gelbman	Director	May 22, 2009

/s/ Pedro Granadillo Pedro Granadillo	Director	May 22, 2009

/s/ Mark Kroll, PH. D. Mark Kroll	Director	May 22, 2009

/s/ Ronald Merriman Ronald Merriman	Director	May 22, 2009

SIGNATURES

HAEMONETICS CORPORATION


	By:	/s/ Brian Concannon

Brian Concannon,
President and Chief Executive Officer

Date: May 22, 2009


Signature	Title	Date


/s/ Brian Concannon Brian Concannon	President and Chief Executive Officer, (Principal Executive Officer)	May 22, 2009

/s/ Christopher Lindop Christopher Lindop	Chief Financial Officer and Vice President Business Development, (Principal Financial Officer)	May 22, 2009

/s/ Susan Hanlon Susan Hanlon	Vice President Finance, (Principal Accounting Officer)	May 22, 2009

/s/ Brad Nutter Brad Nutter	Executive Chairman of the Board	May 22,2009

/s/ Lawrence Best Lawrence Best	Director	May 22, 2009

/s/ Susan Bartlett Foote Susan Bartlett Foote	Director	May 22, 2009

/s/ Ronald Gelbman Ronald Gelbman	Director	May 22, 2009

/s/ Pedro Granadillo Pedro Granadillo	Director	May 22, 2009

/s/ Mark Kroll, PH. D. Mark Kroll	Director	May 22, 2009

/s/ Ronald Merriman Ronald Merriman	Director	May 22, 2009

SIGNATURES

HAEMONETICS CORPORATION


	By:	/s/ Brian Concannon

Brian Concannon,
President and Chief Executive Officer

Date: May 22, 2009


Signature	Title	Date


/s/ Brian Concannon Brian Concannon	President and Chief Executive Officer, (Principal Executive Officer)	May 22, 2009

/s/ Christopher Lindop Christopher Lindop	Chief Financial Officer and Vice President Business Development, (Principal Financial Officer)	May 22, 2009

/s/ Susan Hanlon Susan Hanlon	Vice President Finance, (Principal Accounting Officer)	May 22, 2009

/s/ Brad Nutter Brad Nutter	Executive Chairman of the Board	May 22,2009

/s/ Lawrence Best Lawrence Best	Director	May 22, 2009

/s/ Susan Bartlett Foote Susan Bartlett Foote	Director	May 22, 2009

/s/ Ronald Gelbman Ronald Gelbman	Director	May 22, 2009

/s/ Pedro Granadillo Pedro Granadillo	Director	May 22, 2009

/s/ Mark Kroll, PH. D. Mark Kroll	Director	May 22, 2009

/s/ Ronald Merriman Ronald Merriman	Director	May 22, 2009

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

HAEMONETICS CORPORATION


	By:	/s/ Brian Concannon

Brian Concannon,

President and Chief Executive Officer

Date: May 22, 2009

Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons
on behalf of the Registrant and in the capacities and on the
dates indicated.


Signature	Title	Date


/s/ Brian Concannon Brian Concannon	President and Chief Executive Officer, (Principal Executive Officer)	May 22, 2009

/s/ Christopher Lindop Christopher Lindop	Chief Financial Officer and Vice President Business Development, (Principal Financial Officer)	May 22, 2009

/s/ Susan Hanlon Susan Hanlon	Vice President Finance, (Principal Accounting Officer)	May 22, 2009

/s/ Brad Nutter Brad Nutter	Executive Chairman of the Board	May 22,2009

/s/ Lawrence Best Lawrence Best	Director	May 22, 2009

/s/ Susan Bartlett Foote Susan Bartlett Foote	Director	May 22, 2009

/s/ Ronald Gelbman Ronald Gelbman	Director	May 22, 2009

/s/ Pedro Granadillo Pedro Granadillo	Director	May 22, 2009

/s/ Mark Kroll, PH. D. Mark Kroll	Director	May 22, 2009

/s/ Ronald Merriman Ronald Merriman	Director	May 22, 2009

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

HAEMONETICS CORPORATION


	By:	/s/ Brian Concannon

Brian Concannon,

President and Chief Executive Officer

Date: May 22, 2009

Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons
on behalf of the Registrant and in the capacities and on the
dates indicated.


Signature	Title	Date


/s/ Brian Concannon Brian Concannon	President and Chief Executive Officer, (Principal Executive Officer)	May 22, 2009

/s/ Christopher Lindop Christopher Lindop	Chief Financial Officer and Vice President Business Development, (Principal Financial Officer)	May 22, 2009

/s/ Susan Hanlon Susan Hanlon	Vice President Finance, (Principal Accounting Officer)	May 22, 2009

/s/ Brad Nutter Brad Nutter	Executive Chairman of the Board	May 22,2009

/s/ Lawrence Best Lawrence Best	Director	May 22, 2009

/s/ Susan Bartlett Foote Susan Bartlett Foote	Director	May 22, 2009

/s/ Ronald Gelbman Ronald Gelbman	Director	May 22, 2009

/s/ Pedro Granadillo Pedro Granadillo	Director	May 22, 2009

/s/ Mark Kroll, PH. D. Mark Kroll	Director	May 22, 2009

/s/ Ronald Merriman Ronald Merriman	Director	May 22, 2009

This excerpt taken from the HAE 10-Q filed Feb 3, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	HAEMONETICS CORPORATION


Date: February 2, 2009	By: /s/ Brad Nutter
	Brad Nutter, Chairman and Chief Executive Officer
	(Principal Executive Officer)


Date: February 2, 2009	By: /s/ Christopher Lindop
	Christopher Lindop, Chief Financial Officer and Vice President Business Development (Principal Financial Officer)

This excerpt taken from the HAE 8-K filed Feb 2, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HAEMONETICS CORPORATION
	(Registrant)


Date: February 2, 2009	/s/ Christopher Lindop
	Christopher Lindop, Vice President and Chief Financial Officer

This excerpt taken from the HAE 10-Q filed Nov 6, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	HAEMONETICS CORPORATION


Date: November 5, 2008	By:	/s/ Brad Nutter
	Brad Nutter, Chairman and Chief Executive Officer
	(Principal Executive Officer)


Date: November 5, 2008	By:	/s/ Christopher Lindop
	Christopher Lindop, Chief Financial Officer and Vice President Business Development (Principal Financial Officer)

This excerpt taken from the HAE 8-K filed Oct 27, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to signed on its behalf by the undersigned hereunto duly authorized.

		HAEMONETICS CORPORATION
		{Registrant)


			/s/ Christopher J. Lindop
			Christopher J. Lindop,
			Chief Financial Officer and
Date:	October 27, 2008		Vice President Business Development

This excerpt taken from the HAE 8-K filed Oct 27, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HAEMONETICS CORPORATION
	(Registrant)


Date: October 27, 2008	/s/ Christopher J. Lindop
	Christopher J. Lindop,
	Chief Financial Officer and
	Vice President Business Development

This excerpt taken from the HAE 10-Q filed Aug 6, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	HAEMONETICS CORPORATION


Date: August 6, 2008	By: /s/ Brad Nutter
	Brad Nutter, Chairman and Chief Executive Officer
	(Principal Executive Officer)


Date: August 6, 2008	By: /s/ Christopher Lindop
	Christopher Lindop, Chief Financial Officer and Vice President Business Development (Principal Financial Officer)

EXCERPTS ON THIS PAGE:

10-K (5 sections)	May 22, 2009

10-Q	Feb 3, 2009

8-K	Feb 2, 2009

10-Q	Nov 6, 2008

8-K	Oct 27, 2008

8-K	Oct 27, 2008

10-Q	Aug 6, 2008

"SIGNATURES" elsewhere:

Boston Scientific (BSX)
ABIOMED (ABMD)
Antares Pharma (AIS)
MGC DIAGNOSTICS Corp (ANGN)
AngioDynamics (ANGO)
Alphatec Holdings (ATEC)
AtriCure (ATRC)
BARD C R INC (BCR)
BECTON DICKINSON & CO (BDX)
BioLase Technology (BLTI)
CAS Medical Systems (CASM)
Cantel Medical (CMN)
Cooper Companies (COO)
Conceptus (CPTS)
Home Diagnostics (HDIX)
Integra LifeSciences Holdings (IART)
ICU Medical (ICUI)
ERBA Diagnostics, Inc. (IVD)
Kensey Nash (KNSY)
LeMaitre Vascular (LMAT)
Mesa Laboratories (MLAB)
Merit Medical Systems (MMSI)
Mindray Medical International (MR)
Memry (MRY)
NUCRYST Pharmaceuticals (NCST)
NuVasive (NUVA)
Osteotech (OSTE)
OraSure Technologies (OSUR)
Insulet (PODD)
Protherics (PTIL)
Rochester Medical (ROCM)
Retractable Technologies (RVP)
SenoRx (SENO)
SonoSite (SONO)
STEN (STEN)
Stryker (SYK)
Teleflex (TFX)
Uroplasty (UPI)
Vascular Solutions (VASC)
Orthovita (VITA)
West Pharmaceutical Services (WST)
DENTSPLY International (XRAY)
Young Innovations (YDNT)
Zila (ZILA)
Baxter International (BAX)

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

Haemonetics (HAE)

HAE » Topics » SIGNATURES

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

EXCERPTS ON THIS PAGE:

RELATED TOPICS for HAE:

"SIGNATURES" elsewhere: